Outcomes with durvalumab by tumour PD-L1 expression in unresectable, Stage III non-small-cell lung cancer in the PACIFIC trial
Authors
Paz-Ares, LSpira, A
Raben, D
Planchard, D
Cho, BC
Ozguroglu, M
Daniel, D
Villegas, A
Vicente, D
Hui, R
Murakami, S
Spigel, D
Senan, S
Langer, CJ
Boothman, AM
Broadhurst, H
Wadsworth, C
Dennis, PA
Antonia, SJ
Faivre-Finn, Corinne
Affiliation
Hospital Universitario 12 de Octubre, Lung Cancer Unit CNIO-H12o, CiberOnc and Universidad Complutense, Madrid, SpainIssue Date
2020
Metadata
Show full item recordCitation
Paz-Ares L, Dziadziuszko R, Drilon A, John T, Krebs M, Demetri G, et al. Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors or ROS1-Positive NSCLC with CNS Metastases. Oncology Research and Treatment. 2020;43:235-Journal
Annals of OncologyDOI
10.1016/j.annonc.2020.03.287PubMed ID
32209338Additional Links
https://dx.doi.org/10.1016/j.annonc.2020.03.287Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.annonc.2020.03.287
Scopus Count
Collections
Related articles
- Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC.
- Authors: Gray JE, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, Cho BC, Planchard D, Paz-Ares L, Faivre-Finn C, Vansteenkiste JF, Spigel DR, Wadsworth C, Taboada M, Dennis PA, Özgüroğlu M, Antonia SJ
- Issue date: 2020 Feb
- ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer.
- Authors: Planchard D, Reinmuth N, Orlov S, Fischer JR, Sugawara S, Mandziuk S, Marquez-Medina D, Novello S, Takeda Y, Soo R, Park K, McCleod M, Geater SL, Powell M, May R, Scheuring U, Stockman P, Kowalski D
- Issue date: 2020 May
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
- Authors: Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, Özgüroğlu M, PACIFIC Investigators.
- Issue date: 2018 Dec 13
- Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
- Authors: Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M, PACIFIC Investigators.
- Issue date: 2017 Nov 16
- Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
- Authors: Garassino MC, Cho BC, Kim JH, Mazières J, Vansteenkiste J, Lena H, Corral Jaime J, Gray JE, Powderly J, Chouaid C, Bidoli P, Wheatley-Price P, Park K, Soo RA, Huang Y, Wadsworth C, Dennis PA, Rizvi NA, ATLANTIC Investigators.
- Issue date: 2018 Apr